QPI-1002 is an investigational drug.
There have been 8 clinical trials for QPI-1002.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Ischemia, Delayed Graft Function, and Wounds and Injuries. The leading clinical trial sponsors are Quark Pharmaceuticals and [disabled in preview].
There are two US patents protecting this investigational drug and twenty-one international patents.